TROP - low bone mineral density

This trial is no longer enrolling. This may mean the trial is fully enrolled, or that enrolment in the trial has been halted or suspended. You cannot enrol in this trial.

About this trial

The purpose of this study is to see whether your bone mineral density improves when you switch from tenofovir (a NNRTI) to raltegravir (an integrase inhibitor). The theory is that people who shows signs of osteopenia will see some improvement when they switch from a regimen of tenofovir and a ritonavir-boosted protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate. to one including raltegravir.

Official title:

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

What is this trial studying?

tx_strategy – raltegravir

Start date:

January 2010 (This may be the proposed or expected start date for trials which have not yet started.)

How many participants will this trial enrol?

36 (The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.)

How long is this trial planned to go for?

Participants in this trial will be asked to follow the treatment strategy for 48 weeks.

Links to further information:

• http://clinicaltrials.gov/ct2/show/NCT00939874

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

• At least 18 years old
• Currently taking HIV treatments
• Viral load below 50 copies/ml
• Currently taking tenofovir and a ritonavir boosted PI and have been diagnosed with osteopenia

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

Before making the decision to participate in any clinical research, visit the NAPWA website for background information on participating in clinical research.

Contact NAPWA if you have any questions or comments about this trial.